Open-Angle Glaucoma: Are There Symptoms?
Learn why open-angle glaucoma, often called the “silent thief of sight,” rarely causes symptoms in the early stages of the disease.
Currently approved treatments for glaucoma primarily focus on reducing eye pressure, referred to as elevated intraocular pressure (IOP).
Numerous therapies exist to lower eye pressure effectively; however, the bulk of them (eyedrops and surgeries) require skill and consistency to achieve results.
Easier methods are needed, as well as new therapies to address other underlying causes of glaucoma beyond IOP.
Our researchers are advancing new techniques and strategies for nourishing, regenerating and transplanting retinal nerve cells. Advances in technology and imaging are helping to better monitor and control eye pressure, a key biomarker for glaucoma.
BrightFocus grantees are working to develop new drugs that will more effectively lower eye pressure and protect against nerve cell injury and death. They are also working on and genome editing approaches to restore the function of trabecular meshwork (a spongy tissue that drains fluids from the eye).
In addition, computerized algorithms are being designed to analyze an assortment of biometric data to better predict and track a patient’s risk of progression to vision loss.
Learn why open-angle glaucoma, often called the “silent thief of sight,” rarely causes symptoms in the early stages of the disease.